AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35737855 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/day ETV
Number of subjects: 137
Study 35737855 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/day ETV maleate
Number of subjects: 137
Study 32520696 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week nurse-coordinated, multidisciplinary cardiovascular prevention and rehabilitation programme (CVPRP)
Number of subjects: 0
Study 32520696 — intervention group
Group type: COMPARATOR
Intervention: Usual care hospital (control)
Number of subjects: 0
Study 35986241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention (counselling with pictogram-enhanced medication instructions and smartphone medication reminders)
Number of subjects: 325
Study 33713618 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 200
Study 33713618 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with evidence of hypoattenuated leaflet thickening (HALT) at 30 days
Number of subjects: 200
Study 32737072 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod HCl 0.5 mg/d
Number of subjects: 24
Study 32737072 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod HCl 1 mg/d
Number of subjects: 24
Study 32737072 — intervention group
Group type: COMPARATOR
Intervention: Baseline (day 1)
Number of subjects: 24
Study 36474225 — intervention group
Group type: EXPERIMENTAL
Intervention: Animation education
Number of subjects: 275
Study 36474225 — intervention group
Group type: EXPERIMENTAL
Intervention: Game education
Number of subjects: 275
Study 36474225 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 275
Study 34032717 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 58
Study 34032717 — intervention group
Group type: COMPARATOR
Intervention: Acupressure
Number of subjects: 58
Study 34032717 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg and Acupressure
Number of subjects: 58
Study 32268328 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure-based lifestyle intervention programme
Number of subjects: 173
Study 32268328 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal care
Number of subjects: 173
Study 32268328 — intervention group
Group type: COMPARATOR
Intervention: Prenatal lifestyle intervention sessions
Number of subjects: 173
Study 32268328 — intervention group
Group type: COMPARATOR
Intervention: Normal BMI mothers (control group)
Number of subjects: 173
Study 34151533 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 140
Study 34151533 — intervention group
Group type: COMPARATOR
Intervention: Partial meniscectomy
Number of subjects: 140
Study 34151533 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps muscle strength
Number of subjects: 140
Study 34151533 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstrings muscle strength
Number of subjects: 140
Study 33174296 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap weighting (OW) method for covariate adjustment
Number of subjects: 0
Study 33174296 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse probability weighting (IPW)
Number of subjects: 0
Study 33174296 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of covariance (ANCOVA)
Number of subjects: 0
Study 35678835 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises applied from the 30th week of gestation to the 6th week postpartum
Number of subjects: 60
Study 35678835 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pelvic floor muscle exercise training)
Number of subjects: 60
Study 35678835 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises
Number of subjects: 60
Study 34526429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine Bismuth Citrate (RBC) pretreatment for 2 weeks before standard triple therapy
Number of subjects: 99
Study 34526429 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (esomeprazole, amoxicillin, and clarithromycin for 7 days)
Number of subjects: 99
Study 34526429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine Bismuth Citrate (RBC) pretreatment
Number of subjects: 99
Study 34526429 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 99
Study 36426568 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted psychoeducation intervention (CaPE)
Number of subjects: 300
Study 36426568 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 300
Study 33022718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 33
Study 33022718 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 33
Study 33022718 — intervention group
Group type: COMPARATOR
Intervention: Control (Conventional treatments by atropine and pralidoxime)
Number of subjects: 33
Study 36201971 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment associated with positive end-expiratory pressure titration according to the best respiratory system compliance
Number of subjects: 0
Study 36201971 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-positive end-expiratory pressure strategy
Number of subjects: 0
Study 33210238 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (greater average number of steps per day)
Number of subjects: 73
Study 33210238 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (greater average hours of moderate and moderate/vigorous intensity)
Number of subjects: 73
Study 33210238 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (greater average daily energy expenditure)
Number of subjects: 73
Study 33210238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (higher peak maximum VO2)
Number of subjects: 73
Study 32320894 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered Vascular Stapler (PVS)
Number of subjects: 201
Study 32320894 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) staplers
Number of subjects: 201
Study 35283083 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no pregabalin)
Number of subjects: 54
Study 35283083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (median usage of 2 tablets of 800 mg)
Number of subjects: 54
Study 35283083 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen (median usage of one-half of a 5/325mg tablet)
Number of subjects: 54
Study 33549556 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 to 50 mg/day)
Number of subjects: 527
Study 33549556 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 527
Study 32071130 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA noninvasive ventilation (NIV)
Number of subjects: 0
Study 32071130 — intervention group
Group type: COMPARATOR
Intervention: NIV
Number of subjects: 0
Study 35315170 — intervention group
Group type: COMPARATOR
Intervention: Screening Alone (SA)
Number of subjects: 756
Study 35315170 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Feedback and Brief Advice (PFBA)
Number of subjects: 756
Study 35315170 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Brief Intervention (eBI)
Number of subjects: 756
Study 35522872 — intervention group
Group type: COMPARATOR
Intervention: Treatment for OA and diabetes mellitus according to international recommendations
Number of subjects: 67
Study 35522872 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for OA and diabetes mellitus according to international recommendations + drug alpha-lipoic acid
Number of subjects: 67
Study 32007365 — intervention group
Group type: EXPERIMENTAL
Intervention: T&R-IC
Number of subjects: 902
Study 32007365 — intervention group
Group type: EXPERIMENTAL
Intervention: IC/IS technique
Number of subjects: 902
Study 32007365 — intervention group
Group type: EXPERIMENTAL
Intervention: ring-IC/IS
Number of subjects: 902
Study 32007365 — intervention group
Group type: EXPERIMENTAL
Intervention: IC/IS
Number of subjects: 902
Study 33543763 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-150
Number of subjects: 20
Study 33543763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32442353 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum chloride paste
Number of subjects: 10
Study 32442353 — intervention group
Group type: COMPARATOR
Intervention: Displacement cords
Number of subjects: 10
Study 36311619 — intervention group
Group type: EXPERIMENTAL
Intervention: EYEBIT training method (smartphone virtual reality-based training), 1 hour per day
Number of subjects: 76
Study 36311619 — intervention group
Group type: COMPARATOR
Intervention: Traditional patching method, 2 hours per day
Number of subjects: 76
Study 33373478 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear fluids with carbohydrate plus whey protein (CHO-P)
Number of subjects: 49
Study 33373478 — intervention group
Group type: COMPARATOR
Intervention: Clear fluids with carbohydrate only (CHO)
Number of subjects: 49
Study 34879245 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutaraldehyde-based desensitizer (Gluma Desensitizer - GL) applied with self-etch strategy (SEGL)
Number of subjects: 55
Study 34879245 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutaraldehyde-based desensitizer (Gluma Desensitizer - GL) applied with etch-and-rinse strategy (ERGL)
Number of subjects: 55
Study 34879245 — intervention group
Group type: COMPARATOR
Intervention: No glutaraldehyde-based desensitizer (Control group)
Number of subjects: 55
Study 33935021 — intervention group
Group type: EXPERIMENTAL
Intervention: Full training program (online and in-person simulation training)
Number of subjects: 100
Study 33935021 — intervention group
Group type: COMPARATOR
Intervention: Online training only
Number of subjects: 100
Study 33935021 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 100
Study 32694494 — intervention group
Group type: EXPERIMENTAL
Intervention: Total disc replacement (TDR)
Number of subjects: 126
Study 32694494 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (multidisciplinary rehabilitation)
Number of subjects: 126
Study 35537578 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated RT (68 Gy/25 fractions)
Number of subjects: 96
Study 35537578 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation RT (78 Gy/39 fractions)
Number of subjects: 96
Study 35537578 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 96
Study 32358235 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage contact lens (BCL)
Number of subjects: 30
Study 32358235 — intervention group
Group type: COMPARATOR
Intervention: No bandage contact lens
Number of subjects: 30
Study 32358235 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 32381018 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin (1.4 mg/m2 on days 1 and 8) with Tmab (8 mg/kg then 6 mg/kg) and Pmab (840 mg then 420 mg) on day 1 of each 21-day cycle
Number of subjects: 480
Study 32381018 — intervention group
Group type: COMPARATOR
Intervention: Taxane (docetaxel 75 mg/m2 on day 1 or paclitaxel 80 mg/m2 on days 1, 8, and 15) with Tmab (8 mg/kg then 6 mg/kg) and Pmab (840 mg then 420 mg) on day 1 of each 21-day cycle
Number of subjects: 480
Study 32381018 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin with Tmab and Pmab
Number of subjects: 480
Study 32381018 — intervention group
Group type: COMPARATOR
Intervention: Taxane with Tmab and Pmab
Number of subjects: 480
Study 34180407 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 14
Study 34180407 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential (IF) stimulation
Number of subjects: 14
Study 34180407 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with pulsed ultrasound and IF current (CTPI)
Number of subjects: 14
Study 34180407 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 14
Study 34480960 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT-SIB (50.4 Gy in 1.8 Gy fractions with a 64.4 Gy SIB to the tumor bed)
Number of subjects: 502
Study 34480960 — intervention group
Group type: COMPARATOR
Intervention: 3D-CRT-seqB (50.4 Gy in 1.8 Gy fractions followed by a sequential boost of 16 Gy in 2 Gy fractions)
Number of subjects: 502
Study 34519344 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual MDA
Number of subjects: 64
Study 34519344 — intervention group
Group type: COMPARATOR
Intervention: Annual MDA after peak of transmission
Number of subjects: 64
Study 34519344 — intervention group
Group type: COMPARATOR
Intervention: Standard MDA combined with snail control
Number of subjects: 64
Study 34519344 — intervention group
Group type: COMPARATOR
Intervention: Annual MDA before peak of transmission (standard strategy)
Number of subjects: 64
Study 34458106 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to negative news about COVID-19
Number of subjects: 245
Study 34458106 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to positive news about COVID-19
Number of subjects: 245
Study 34458106 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation pause activity after listening to news
Number of subjects: 245
Study 35322672 — intervention group
Group type: COMPARATOR
Intervention: GALACTIC-HF–ineligible cohort not taking guideline-directed medical therapy (GDMT)
Number of subjects: 9770
Study 35322672 — intervention group
Group type: COMPARATOR
Intervention: GALACTIC-HF–eligible cohort with EF ≤28%
Number of subjects: 9770
Study 35322672 — intervention group
Group type: COMPARATOR
Intervention: GALACTIC-HF–eligible cohort with EF 29% to 35%
Number of subjects: 9770
Study 35322672 — intervention group
Group type: COMPARATOR
Intervention: GALACTIC-HF–eligible cohorts
Number of subjects: 9770
Study 616982967 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR)
Number of subjects: 12
Study 616982967 — intervention group
Group type: EXPERIMENTAL
Intervention: Running (RR)
Number of subjects: 12
Study 616982967 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 12
Study 35610738 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma (FFP) resuscitation
Number of subjects: 0
Study 35610738 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FFP resuscitation)
Number of subjects: 0
Study 32323020 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal physiological stress (hair cortisol)
Number of subjects: 603
Study 32323020 — intervention group
Group type: EXPERIMENTAL
Intervention: Child physiological stress (hair cortisol)
Number of subjects: 603
Study 32323020 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic and psychosocial adversity
Number of subjects: 603
Study 34736874 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender essential oil
Number of subjects: 86
Study 34736874 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosemary essential oil
Number of subjects: 86
Study 34736874 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange essential oil
Number of subjects: 86
Study 34736874 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 32041634 — intervention group
Group type: EXPERIMENTAL
Intervention: New child food package for 4 years
Number of subjects: 74871
Study 32041634 — intervention group
Group type: COMPARATOR
Intervention: New child food package for < 4 years
Number of subjects: 74871
Study 35705334 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 202
Study 35705334 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AADs) with risk factor modification (RFM)
Number of subjects: 202
Study 35705334 — intervention group
Group type: COMPARATOR
Intervention: RFM+AAD
Number of subjects: 202
Study 34774400 — intervention group
Group type: EXPERIMENTAL
Intervention: NATURE technique (Nerves And Transversalis-fascia Using RopivacainE)
Number of subjects: 97
Study 34774400 — intervention group
Group type: COMPARATOR
Intervention: Control group (local anaesthesia only over surgical incisions)
Number of subjects: 97
Study 32077321 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal conflict cognitive reappraisal intervention (neutral third-party perspective)
Number of subjects: 260
Study 32077321 — intervention group
Group type: COMPARATOR
Intervention: Control condition (writing about their day)
Number of subjects: 260
Study 34895712 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) 1 g (10 mL)
Number of subjects: 121
Study 34895712 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) (10 mL)
Number of subjects: 121
Study 34859955 — intervention group
Group type: EXPERIMENTAL
Intervention: Garadacimab (0.1, 0.3, 1, 3, and 10 mg/kg i.v. and 1, 3, and 10 mg/kg s.c.)
Number of subjects: 48
Study 34859955 — intervention group
Group type: EXPERIMENTAL
Intervention: Garadacimab (3 and 10 mg/kg i.v. and s.c.)
Number of subjects: 48
Study 34859955 — intervention group
Group type: EXPERIMENTAL
Intervention: Garadacimab (single-dose i.v. and s.c.)
Number of subjects: 48
Study 34859955 — intervention group
Group type: EXPERIMENTAL
Intervention: Garadacimab
Number of subjects: 48
Study 34859955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 34569981 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (30 minutes of treadmill exercise at moderate to high intensity)
Number of subjects: 20
Study 34569981 — intervention group
Group type: COMPARATOR
Intervention: Resting control condition
Number of subjects: 20
Study 36056396 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) program (60 min/session; 3 times/week, for 6 months)
Number of subjects: 60
Study 36056396 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical follow-up (non-exercised control group)
Number of subjects: 60
Study 32503030 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 16
Study 32503030 — intervention group
Group type: COMPARATOR
Intervention: Control (neonates matched for hours of life who were cooled but unexposed to aminophylline)
Number of subjects: 16
Study 36069803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (2 × 600‐mg doses)
Number of subjects: 9
Study 35734717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoid colon vaginoplasty
Number of subjects: 39
Study 34894070 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone (0.5 mg/kg/d)
Number of subjects: 32
Study 34894070 — intervention group
Group type: COMPARATOR
Intervention: High-dose prednisolone (1 mg/kg/d)
Number of subjects: 32
Study 33215359 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluded/ingroup (ostracism)
Number of subjects: 69
Study 33215359 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluded/outgroup (racial discrimination)
Number of subjects: 69
Study 33215359 — intervention group
Group type: COMPARATOR
Intervention: Included conditions
Number of subjects: 69
Study 33215359 — intervention group
Group type: COMPARATOR
Intervention: Ingroup conditions
Number of subjects: 69
Study 33054405 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 50
Study 33054405 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 35606811 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated supportive program (including face-to-face education, coaching at 1 month, and telephone coaching at 2, 3, 6, and 9 months)
Number of subjects: 79
Study 35606811 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated supportive program
Number of subjects: 79
Study 35606811 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 79
Study 33556321 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tenofovir disoproxil fumarate
Number of subjects: 0
Study 33556321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32599773 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein with higher Tryptophan/Large Neutral Amino Acids (LNAAs) ratio
Number of subjects: 48
Study 32599773 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein with different Tryptophan/Large Neutral Amino Acids (LNAAs) ratios
Number of subjects: 48
Study 33930239 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-FLAIR
Number of subjects: 294
Study 33930239 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-DIR
Number of subjects: 294
Study 33930239 — intervention group
Group type: COMPARATOR
Intervention: 3D-T1
Number of subjects: 294
Study 33930239 — intervention group
Group type: COMPARATOR
Intervention: 2D-T2
Number of subjects: 294
Study 35445570 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype PTB in Gumline mode
Number of subjects: 39
Study 35445570 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype PTB in Combined mode
Number of subjects: 39
Study 35445570 — intervention group
Group type: COMPARATOR
Intervention: Reference PTB
Number of subjects: 39
Study 35445570 — intervention group
Group type: COMPARATOR
Intervention: Reference MTB
Number of subjects: 39
Study 32811531 — intervention group
Group type: EXPERIMENTAL
Intervention: hUC-MSC treatment group
Number of subjects: 0
Study 32811531 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study 34762989 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium silicate/fluoride toothpaste slurry
Number of subjects: 60
Study 34762989 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-only toothpaste slurry
Number of subjects: 60
Study 34762989 — intervention group
Group type: COMPARATOR
Intervention: Control (no fluoride)
Number of subjects: 60
Study 33407780 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIRIT-AI and CONSORT-AI guidelines
Number of subjects: 0
Study 35409267 — intervention group
Group type: EXPERIMENTAL
Intervention: HH30 (30 min hypobaric hypoxia)
Number of subjects: 80
Study 35409267 — intervention group
Group type: EXPERIMENTAL
Intervention: HH60 (60 min hypobaric hypoxia)
Number of subjects: 80
Study 35409267 — intervention group
Group type: COMPARATOR
Intervention: GC30 (30 min ground control)
Number of subjects: 80
Study 33727278 — intervention group
Group type: EXPERIMENTAL
Intervention: group sessions
Number of subjects: 621
Study 33727278 — intervention group
Group type: EXPERIMENTAL
Intervention: combined groups and home visits
Number of subjects: 621
Study 33727278 — intervention group
Group type: COMPARATOR
Intervention: control arm
Number of subjects: 621